Harnessing multi-omic profiling and proprietary AI to create truly individualized cancer treatments — designed for each patient's unique tumor.
Discover Our Approach →From biopsy to personalized treatment in 45 days, a truly scalable advanced manufacturing platform.
We analyze the individual patient's cancer cells using comprehensive DNA/RNA sequencing combined with advanced mass spectrometry.
Our proprietary BreakBioAI platform ranks 40+ mutated and non-mutated unique targets from each patient's tumor cells.
Every patient receives a customized peptide immunotherapy to stimulate T-cells for their specific targets.
Beginning in 2026, BreakBio is currently enrolling patients for our first trial targeting Triple Negative Breast Cancer (TNBC).
Pioneers in cancer research, AI, proteomics, and personalized medicine.
Roy de Souza had built a successful career in technology, founding ZEDO — one of the world's largest ad-serving platforms. But in 2017, when his wife Aisha de Sequeira was diagnosed with metastatic colon cancer, everything changed.
Rather than accept limited conventional options, Roy spent six months studying cancer research intensively. He partnered with leading scientists to develop a personalized cancer vaccine for Aisha — one that had to be manufactured and administered in Germany because U.S. regulations didn't yet allow it.
That experience revealed how far behind cancer treatment was compared to what technology could enable — and it sparked the creation of BreakBio. Roy and Aisha were honored by the American Cancer Society in 2023 for their contributions to advancing personalized cancer treatment.
A documentary about their journey is being produced by USC professor Alex Rotaru.